IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v19y2022i23p16057-d989693.html
   My bibliography  Save this article

Lurasidone use in Cannabis-Induced Psychosis: A Novel Therapeutic Strategy and Clinical Considerations in Four Cases Report

Author

Listed:
  • Valerio Ricci

    (San Luigi Gonzaga Hospital, University of Turin, 10043 Orbassano, Italy)

  • Giovanni Martinotti

    (Department of Neurosciences, Imaging and Clinical Sciences, Università Degli Studi G. D’Annunzio Chieti-Pescara, 66100 Chieti, Italy)

  • Domenico De Berardis

    (National Health Service, Department of Mental Health, Psychiatric Service for Diagnosis and Treatment, Hospital “G. Mazzini”, 64100 Teramo, Italy)

  • Giuseppe Maina

    (San Luigi Gonzaga Hospital, University of Turin, 10043 Orbassano, Italy
    Department of Neurosciences “Rita Levi Montalcini”, University of Turin, 10043 Orbassano, Italy)

Abstract

Background: Lurasidone is an atypical antipsychotic approved for the acute and maintenance treatment of schizophrenia. Recently, lurasidone was also extended FDA approval for adults with major depressive episodes associated with bipolar I disorder (bipolar depression), as either a monotherapy or as adjunctive therapy with lithium or valproate. The use of low doses of atypical antipsychotics is an essential component of early intervention in psychosis, but little has yet been studied on first episode cannabis-induced psychosis. For its particular performance and tolerability, lurasidone is becoming an important option for the treatment of first-episode psychosis in youth. Case presentation four patients experiencing first cannabis-induced psychotic episode were treated with lurasidone. In all patients, there was an improvement in the clinical picture of psychosis. The recovery was positive, not only with the remission of positive and negative symptoms, but also regarding disruptive behaviour, with the return of functioning. All the patients were treated with lurasidone, with a target dose of 74–128 mg/day. No significant side effects were reported. Conclusion: There are non-controlled studies for the use of lurasidone in first episode psychosis cannabis induced. These findings suggest that lurasidone is an atypical antipsychotic beneficial in this clinical picture. Treatment with medium-high doses of lurasidone could be effective and tolerable in this phase of the disorder. Randomized control trials with longer follow-up are recommended to confirm these positive results.

Suggested Citation

  • Valerio Ricci & Giovanni Martinotti & Domenico De Berardis & Giuseppe Maina, 2022. "Lurasidone use in Cannabis-Induced Psychosis: A Novel Therapeutic Strategy and Clinical Considerations in Four Cases Report," IJERPH, MDPI, vol. 19(23), pages 1-9, November.
    • Handle: RePEc:gam:jijerp:v:19:y:2022:i:23:p:16057-:d:989693
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/19/23/16057/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/19/23/16057/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. G. Baudin & O. Godin & M. Lajnef & Bruno Aouizerate & F. Berna & L. Brunel & D. Capdevielle & I. Chereau & J. M. Dorey & C. Dubertret & J. Dubreucq & C. Faget & G. Fond & F. Gabayet & H. Laouamri & C., 2016. "Differential effects of childhood trauma and cannabis use disorders in ă patients suffering from schizophrenia," Post-Print hal-01482654, HAL.
    2. Valerio Ricci & Giovanni Martinotti & Franca Ceci & Stefania Chiappini & Francesco Di Carlo & Julius Burkauskas & Ottavia Susini & Debora Luciani & Diego Quattrone & Domenico De Berardis & Mauro Petto, 2021. "Duration of Untreated Disorder and Cannabis Use: An Observational Study on a Cohort of Young Italian Patients Experiencing Psychotic Experiences and Dissociative Symptoms," IJERPH, MDPI, vol. 18(23), pages 1-13, November.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Cem İngeç & Esin Evren Kılıçaslan, 2020. "The effect of childhood trauma on age of onset in patients with schizophrenia," International Journal of Social Psychiatry, , vol. 66(8), pages 763-769, December.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:19:y:2022:i:23:p:16057-:d:989693. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.